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Acute myeloid leukemia (AML) is associated with mu-
tations in transcriptional and epigenetic regulator
genes impairing myeloid differentiation. The t(8;21)
(q22;q22) translocation generates the RUNX1-ETO
fusion protein, which interferes with the hematopoiet-
ic master regulator RUNX1. We previously showed
that the maintenance of t(8;21) AML is dependent on
RUNX1-ETO expression. Its depletion causes exten-
sive changes in transcription factor binding, as well
as gene expression, and initiates myeloid differentia-
tion. However, how these processes are connected
within a gene regulatory network is unclear. To
address this question, we performed Promoter-Cap-
ture Hi-C assays, with or without RUNX1-ETO deple-
tion and assigned interacting cis-regulatory elements
to their respective genes. To construct a RUNX1-
ETO-dependent gene regulatory network maintaining
AML, we integrated cis-regulatory element interac-
tions with gene expression and transcription factor
binding data. This analysis shows that RUNX1-ETO
participates in cis-regulatory element interactions.
However, differential interactions following RUNX1-
ETO depletion are driven by alterations in the binding
of RUNX1-ETO-regulated transcription factors.INTRODUCTION
Acute myeloid leukemia (AML) is a hematopoietic malignancy
caused by genetic abnormalities in hematopoietic stem cells
(HSCs), which restrict their ability to undergo the normal differen-
tiation process (Bonifer and Cockerill, 2015; Kumar, 2011). The3022 Cell Reports 28, 3022–3031, September 17, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativetranscription factors (TFs) regulating hematopoiesis have to be
expressed in a stage- and lineage-restricted fashion since their
mutation or de-regulation impairs differentiation and prolongs
the proliferative stage, thus increasing the opportunities for cells
to further mutate and progress to AML (Bonifer and Cockerill,
2011; Rosenbauer and Tenen, 2007). One of the best-studied
subtypes of AML is the t(8;21)(q22;q22) translocation generating
the RUNX1-ETO fusion protein (Erickson et al., 1992; Miyoshi
et al., 1991). RUNX1-ETO has a modular structure comprising
the RUNX1 DNA-binding domain plus four evolutionary
conserved functional domains named nervy homology regions
1 to 4 (NHR1 to NHR4) (Kitabayashi et al., 1998), which recruit
transcriptional repressors such as the N-CoR/mSin3/HDAC1
complex (Lutterbach et al., 1998). The expression of this
abnormal protein results in a block in differentiation and
increased cell survival (Dunne et al., 2006; Heidenreich et al.,
2003; Martinez et al., 2004; Ptasinska et al., 2012).
The RUNX1-ETO fusion protein is part of a larger TF complex
consisting of RUNX1-ETO; CBFb; the erythroblast transforma-
tion-specific (ETS) family of transcription factors (ERG and
FLI1); E proteins such as HEB, E2A, and LYL1; and the non-
DNA binding factors LDB1 and LMO2 (Martens et al., 2012; Pta-
sinska et al., 2014; Sun et al., 2013). Each part of the complex is
thought to be essential for AML maintenance (Sun et al., 2013).
RUNX1-ETO depletion in t(8;21) cells is sufficient to trigger
extensive global changes in the transcriptomic and epigenetic
profile across hundreds of genes (Ben-Ami et al., 2013; Dunne
et al., 2006; Ptasinska et al., 2012; Sun et al., 2013). Depletion
upregulates a specific set of RUNX1-regulated genes, such as
CEBPA, leading to increased recruitment of RUNX1 and C/
EBPa to gene regulatory elements throughout the genome,
thereby releasing the block on myeloid differentiation and sup-
pressing self-renewal (Loke et al., 2017; Ptasinska et al., 2014;
Sun et al., 2013). We have previously used global TF binding
and gene expression information to construct a dynamic gene
regulatory network linking genes bound by the RUNX1-ETOuthor(s).
commons.org/licenses/by/4.0/).
complex to dynamic changes of gene expression (Ptasinska
et al., 2014). We used such system-wide information to devise
a RNAi dropout screen that identified a number of genes associ-
ated with AML maintenance (Martinez-Soria et al., 2019). How-
ever, to fully explore the power of genome-wide studies, we
need to construct gene regulatory networks that enable us to
predict the results of perturbation experiments from such data
using modeling approaches. Therefore, a number of issues still
need to be resolved. RUNX1-ETO mostly binds to distal cis-reg-
ulatory elements, and although we can define genes responding
to RUNX1-ETO knockdown, we do not know whether this
response is direct or indirect, as we do not knowwhich promoter
is linked to the sites of fusion protein binding. In addition, we do
not know which other TFs participate in the maintenance of
the leukemic state and drive the response to RUNX1-ETO
knockdown.
To answer these questions, we identified direct cis-element
interactions using the Promoter Capture Hi-C (CHi-C) method
(Mifsud et al., 2015) in Kasumi-1 cells, a well-known model of
t(8;21) AML, with and without small interfering RNA (siRNA)-
mediated RUNX1-ETO depletion. RUNX1-ETO knockdown
leads to a rewiring of promoter-enhancer interactions, which
is driven by increased C/EBPa and loss of AP-1 binding after
knockdown. We integrated these results with chromatin immu-
noprecipitation (ChIP) and digital footprinting data from cell lines
and patients to identify regulatory relationships between binding
events and gene expression, which will aid further studies
aimed at identifying pathways required for t(8;21) AML leukemic
maintenance.
RESULTS AND DISCUSSION
RUNX1-ETO Depletion Does Not Lead to a Global
Reorganization of Chromosome Structure but Changes
Promoter-Enhancer Interactions within TADs
The tissue specificity of gene expression is controlled by line-
age-restricted TFs binding to distal cis-regulatory elements
that need to physically interact with their target promoters in
order to activate gene expression (de Laat and Duboule,
2013; Plank and Dean, 2014). To examine whether RUNX1-
ETO influences genome-wide cis-element interactions, we
generated duplicate CHi-C libraries (Mifsud et al., 2015) from
Kasumi-1 cells that were either untreated (mismatch control
siRNA [siMM]) or following a 4-day siRNA-mediated treatment
to knockdown RUNX1-ETO (siRE) (Figure 1A). Data analysis of
the sequenced libraries identified 57,775 significant interactions
between promoters and distal elements before and 60,681 sig-
nificant interactions after RUNX1-ETO depletion. CHi-C libraries
were highly reproducible with an average of 70% overlap of sig-
nificant interactions between replicates (Figures S1A–S1D). To
align our CHi-C data with the coordinates of cis-regulatory ele-
ments, we mapped Deoxyribonuclease I (DNaseI) hypersensi-
tive sites (DHSs) during a knockdown time course (Figure S1E).
The presence (siMM) or absence (siRE) of RUNX1-ETO did not
influence global chromosomal organization across all chromo-
somes (Figure 1A), including the organization of this region
into topologically associated domains (TADs; large triangles,
projected above the DHS pattern) (Gonzalez-Sandoval andGasser, 2016; Figure 1B). Figure 1C shows a University of Cal-
ifornia, Santa Cruz (UCSC) genome browser screenshot high-
lighting active and inactive chromatin compartments plotted
alongside RUNX1-ETO ChIP data (Ptasinska et al., 2012) and
day-10 DNase I hypersensitive sites sequencing (DNaseI-seq)
data (this manuscript). These analyses revealed clusters of in-
teractions within active and inactive regions whose ratio was
invariant even after an extended period of RUNX1-ETO deple-
tion (Figure 1D).
To investigate whether specific DHS patterns seen following
RUNX1-ETO depletion correlated with a specific stage of
myeloid differentiation, we compared DNaseI data from control
and RUNX1-ETO-depleted Kasumi-1 cells (days 2, 4, and 10) to
published assay for transposase-accessible chromatin using
sequencing (ATAC-seq) data defining the open chromatin re-
gions of normal stem and progenitor cells representing different
developmental stages (Corces et al., 2016; Figure S1F). DHSs
specific for control cells (bottom) aligned more closely with
HSCs and early progenitors and showed increased AP-1 motif
enrichment, whereas DHSs specific for RUNX1-ETO-depleted
cells (top) aligned with those of monocytic cells and were en-
riched for C/EBP motifs. RUNX1-ETO depletion had a profound
effect on gene expression with a large number of genes chang-
ing expression by day 10 (Figure S1G). Flow cytometry and prin-
cipal component analyses of DNaseI-seq data revealed that
Kasumi-1 cells gradually lose their stem cell markers (CD34
and CD117) while principal component and correlation clus-
tering analyses of the DNaseI-seq data indicated that at day
10, but not yet at day 4, they had differentiated toward mono-
cytic cells (Figures S1J and S1K). Phenotypic changes were
accompanied by changes in protein and mRNA expression for
a number of TFs visible already at day 2, in particular C/EBPa
(Figures S1L and S1M), which is rapidly upregulated after
knockdown. JUN mRNA was strongly downregulated during
the first days of knockdown but then was strongly upregulated
in concordance with its important role in regulating monocyte
and/or macrophage-specific gene expression (Heinz et al.,
2010). The expression of JUND protein was upregulated as
well, but note that the DNA-binding activity of the AP-1 family
of TFs is regulated by signaling-mediated phosphorylation (Bej-
jani et al., 2019).
Around 80% of all DHSs detected in active regions of control
cells or RUNX1-ETO-depleted cells participated in promoter-
enhancer interactions (Figure 1E, right panels). To identify
differential interactions, we used the CHi-C data to assign the
respective DHSs to the promoter for RUNX1-ETO-depleted
and control cells (Data S1). Figures 2A and 2B show statistically
significant control-specific and RUNX1-ETO-specific interac-
tions at 5-kb resolution involving specific DHSs on chromosome
3, which were not seen with shared DHSs (Figure S2A), indi-
cating that it is the differential DHSs that drive these changes.
A total of 1104 DHSs were significantly increased and 1209
were significantly decreased after 10 days of RUNX1-ETO
knockdown (Figures 2E and S1F). The majority of these DHS
(75% and 76%, respectively) show differential promoter-
enhancer interactions already after day 4 of knockdown (Fig-
ure 1E), demonstrating that RUNX1-ETO depletion alters the
epigenome prior to monocytic differentiation.Cell Reports 28, 3022–3031, September 17, 2019 3023
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Figure 1. RUNX1-ETO and the Genome Organization in t(8;21) AML
(A) Contact matrix across the whole genome. Each pixel represents a 10-Mb section of the genome. Color intensity represents interaction frequency. The left-
hand plot shows a Capture HiC interaction matrix generated with data from Kasumi-1 cells transfected with mismatch control siRNA (siMM) for 4 days; the right-
hand plots shows an interaction matrix from RUNX1-ETO-depleted Kasumi-1 cells transfected with the specific siRNA (siRE).
(B) Contact matrix across chromosome 3 at 10-Mb resolution. The heatmap shows the raw interactions on chromosome 3 using Kasumi-1 cells transfected with
siMM (left) and siRE (right); a UCSC track highlighting the DHS pattern is shown below each heatmap together with the CHi-C first principle component (PC1) plot
(see below).
(C) UCSC genome browser screenshot shows a first principle component plot for Capture HiC siMM and siRE samples plotted along with RUNX1-ETO ChIP data
(Ptasinska et al., 2014) and DNaseI-seq control (siMM) and knockdown (siRE) data from Kasumi-1 cells for a 70-Mb regions on chromosome 11.
(D) Percentage of DHSs in active and inactive chromatin compartments in Kasumi-1 cells transfected with siMM and siRE.
(E) Percentage of DHSs found at day 10 of knockdown participating in promoter-enhancer interactions (determined at day 4 of knockdown) detected in all active
chromatin regions of siMMcells or siRE cells (right two panels), and specific to siMMor siRE cells (left two panels), indicating that themajority of specific DHSs are
already present at day 4.RUNX1-ETO-Regulated TFs Drive Differential
Cis-Regulatory Element Interactions
We next sought to identify the TFs driving the changes in interac-
tions by performing digital footprinting analysis, using our
Wellington algorithm (Piper et al., 2013). This approach reveals
TF motifs protected from DNaseI digestion and evaluates
genome-wide TF occupancy with high accuracy (Figure 2C). Ex-
amples of such footprints for day 10 of knockdown are depicted3024 Cell Reports 28, 3022–3031, September 17, 2019for ETS and C/EBP motifs at the IL17RA locus in Kasumi-1 cells
(Figure S2B). Global binding motif analysis confirmed that AP-1
motifs were preferentially occupied in control (siMM) cells
whereas C/EBP motifs were occupied in RUNX1-ETO-depleted
(siRE) cells (Figure 2D). Motif occupancy was validated by
comparing footprinting data with previously generated ChIP-
seq data for C/EBPa, RUNX1-ETO, PU.1, JUND, and RUNX1
(Ptasinska et al., 2014; Martinez-Soria et al., 2019) (Figure S2C).
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Two factors capable of mediating long-range interactions are
CTCF and LDB1 (Deng et al., 2012; Splinter et al., 2006). To
examine their role, we generated new CTCF and LDB1 ChIP
data with and without RUNX1-ETO depletion. We correlated
changes in gene expression and TF binding at specific DHSs
with differential interactions between DHSs and promoters (Fig-
ure 2E). These analyses revealed a global increase in C/EBPa
binding after knockdown and a decrease in JUND binding at
siMM-specific DHSs (Figure 2E). All other factors showed no or
little difference in binding between knockdown and control cells.
Changing interactions correlated with differential gene expres-
sion (Figure 2E, outermost right panel). Figure 2F shows an
example of interactions at the upregulated CCND2 gene, which
shows changes in interactions between its promoter and two up-
stream distal elements (depicted in red). Two observations are
noteworthy. First, the CCND2 promoter interacts with a large
number of distal DHSs. Second, a large number of RUNX1-
ETO binding sites are located within these sites, indicating that
RUNX1-ETO is part of an extended and mostly invariant chro-
matin hub. To validate our Chi-C data, we conducted a circular-
ized chromosome conformation capture (4C) experiment that
investigated the SPI1 (PU.1) locus at high resolution, using two
different viewpoints (Figure S2D). We detected known interac-
tions between the SPI1 promoter and an upstream enhancer
(URE) (Ebralidze et al., 2008), but also with two upstream pro-
moters. These interactions did not change after RUNX1-ETO
depletion. The same result was found using CHi-C (Figure S2E).
We next analyzed the behavior of LDB1 in more detail. LDB1
does not bind to DNA directly but via other TFs such as
RUNX1 (Wadman et al., 1997). LDB1 binds to both promoter
and distal regions (Figure S2E) and RUNX1-ETO depletion led
to a loss of 1,506 LDB1 binding sites and the acquisition of
779 new sites (Figure S2F). De novo motif search of siMM- or
siRE-specific LDB1 peaks revealed an enrichment of RUNX1
motifs in both binding site populations, which, however,
occurred together with the AP-1 motif in siMM-specific peaks
and with C/EBP binding motifs after RUNX1-ETO knockdown
(Figure S2G). As expected from it being part of the RUNX1-
ETO and RUNX1 complex, LDB1 binding correlated with interac-
tions in control DHSs, which were lost after RUNX1-ETO
depletion but also participated in new interactions (Figure S2F,Figure 2. Differential Promoter-Enhancer Interactions after RUNX1-ET
(A) Heatmap representing the correlation of normalized interaction ratios across ch
to DHS peaks that are depleted after RUNX1-ETO knockdown. Each pixel represe
for siMM and the right panel for siRE cells. Positive correlations are shown as r
interactions, reads from replicates 1 and 2 were merged.
(B) Heatmap representing the correlation of normalized interaction ratios across ch
that are newly formed after RUNX1-ETO (R/E) gene knockdown. For all other fea
(C) DNaseI cleavage patterns within specific distal footprints predicted byWelling
cut sites in green within a 200-bp window centered on each footprint (gap) for si
(D) Analysis of overrepresented binding motifs within each footprint class as defi
(E) Left panel: time course of DHS development after 2, 4, and 10 days of RUNX1
alongside day-10 knockdown (KD) and control-specific (bottom) counts; common
coordinates, C/EBPa, JUND, LDB1, CTCF, RUNX1-ETO, LMO2, PU.1, and RUN
are plotted as indicated (middle panel). The right panel shows the expression lev
(F) UCSC browser screenshot depicting interactions between the CCND2 promo
data before and after RUNX1-ETO knockdown. Changing interactions are shown
shaded bar.
(G) The same analysis as in (F) for the CITED2 locus.
3026 Cell Reports 28, 3022–3031, September 17, 2019third panel). To test whether LDB1 was required for RUNX1-
ETO binding, we depleted it using siRNA knockdown in
Kasumi-1 cells with and without RUNX1-ETO knockdown (Fig-
ure S3A). LDB1 depletion led to an increase in cell death both
by apoptosis and necrosis, but only in RUNX1-ETO-expressing
cells, confirming that it is required for the maintenance of the
leukemic phenotype (Sun et al., 2013) (Figure S3B). However,
LDB1 was not required for RUNX1-ETO binding to chromatin
(Figure S3C). LDB1 was also not required for the upregulation
or repression of RUNX1-ETO target genes. As expected,
RUNX1-ETO knockdown led to increases in expression of the
direct RUNX1-ETO target genes C/EBPA, CTSG, and NFE2
and decreases in CD34 and ERG expression. Knockdown of
LDB1 alone or together with RUNX1-ETO knockdown had no ad-
ditive or negative effect on RUNX1-ETO target gene expression
changes (Figure S3D). We therefore conclude that other factors
besides RUNX1-ETO control LDB1 binding and determine its
functional impact.
We next investigated whether the change in interaction was
associated with altered TF occupancy. To this end, differential
interactions were ranked by fold change in p value (Figure 3A),
and associated DHSs were plotted alongside together with C/
EBPa, JUND, LDB1, CTCF, RUNX1-ETO, PU.1, and RUNX1
ChIP-seq data. Beneath, we plotted the average profiles of fac-
tor binding for control and RUNX1-ETO-depleted cells (blue,
ChIP signals associated with lost interactions; red, gained inter-
actions). Differential interactions were associated with the differ-
ential binding of some, but not all, TFs. RUNX1-ETO-bound sites
were associated with DHSs involved in both decreased and
increased interactions, demonstrating that it is not the sole
determinant of the interaction pattern. DHS associated with
gained interactions showed a strong increase in C/EBPa as
well as an increase in RUNX1 binding. Conversely, DHSs associ-
ated with decreased interactions after RUNX1-ETO knockdown
lost JUND as well as LDB1 binding. An example for a downregu-
lated gene is CCND2 (Figure S2F), whose expression we have
previously shown to be dependent on the presence of AP-1 fac-
tors (Martinez-Soria et al., 2019). Increased interactions did not
involve an increase in LMO2 or PU.1 binding, and loss of interac-
tions did not involve CTCF. The CITED2 gene is an example of a
genewith a new interaction driven byC/EBPabinding (Figure 2G,O Depletion Are Driven by Differential TF Binding
r3 at 5-kb resolution, showing the correlation of CHiC peaks in regions specific
nts a 5-kb section of the genome. The left panel shows the interaction heatmap
ed; negative correlation as blue squares. To determine statistically significant
r3 at 5-kb resolution and showing the correlation of CHi-C peaks in DHS peaks
tures, see (A).
ton (Piper et al., 2013). Upper strand cut sites are shown in red and lower strand
MM- and siRE-specific footprints.
ned in (C).
-ETO depletion (see scheme in Figure S1E). Normalized tag counts are ranked
and siRE-specific DHS are indicated on the left. Alongside the same genomic
X1 ChIP-seq reads from Kasumi-1 cells with or without RUNX1-ETO depletion
els of the genes linked to the associated DNaseI-seq sites (right panel).
ter and surrounding DHS (shown as arcs) together with the indicated ChIP-seq
in red, and their associated DHS/ChIP peaks are highlighted using a vertical
CA
E
D
B
Figure 3. The Cooperation of Constitutive and Inducible TFs Is Associated with Differential Interactions
(A) Log p values of the differential interactions were plotted ranked from high to low for control and RUNX1-ETO-depleted cells. Red represents an increase in
interaction strength and blue represents a decrease. Alongside, the DNaseI-seq fold difference between control and RUNX1-ETO knockdown cells as well as
ChIP-seq density profiles for C/EBPa, JUND, LDB1, CTCF, RUNX1-ETO, LMO2, and PU.1 are plotted from Kasumi-1 cells, transfected with either siMM or siRE
as indicated. The panels below show the average profiles of the binding of the indicated TFs plotted around the peak summit for control and RUNX1-ETO-
depleted cells. Red, ChIP signal specific for peaks with increased interactions; blue, ChIP signal specific for peaks with decreased interactions.
(B) Determination of enriched motifs for other TFs in ChIP-seq peaks specific for control and RUNX1-ETO-depleted cells. Motif enrichment was first identified
using HOMER and then filtered against digital footprinting data from day 10 of knockout to ensure that these binding motifs were functional. Enrichment scores
were subjected to unsupervised clustering for each of the indicatedmotifs (on the right). The heatmap depicts the degree of motif enrichment with highly enriched
motifs shown in red. Peaks were overlaid with the DHS that show new interactions (red brackets at the bottom) or whose interactions are lost (blue brackets).
Enrichment scores were calculated by the level of motif enrichment in the unique peaks, as compared to motif enrichment in RUNX1-ETO peaks. Bottom panels:
percentage of peaks showing differential interaction with TFs binding to these sites as determined by ChIP-seq (control cells, blue; RUNX1-ETO-depleted
cells, red).
(legend continued on next page)
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shaded bar). In summary, our study shows that the main drivers
of changes in cis-element interactions are the loss of RUNX1-
ETO binding together with the loss of LDB1 and AP-1 binding
along with the increased binding of C/EBPa and RUNX1 to
new sites.
We next identified additional TFs associated with differential
interactions and clustered TF binding motifs enriched in ChIP-
seq peaks that either overlapped with new interaction sites or
with sites lost after RUNX1-ETO depletion (Figure 3B, left panel
and panels below the heatmap). Since the majority of DHS
changes participating in differential interactions had already
occurred at day 4 of knockdown (Figure 1E), we used our day-
10 digital footprinting data to ensure that thesemotifs were func-
tional and could be occupied. We then calculated the motif
enrichment score of such motifs (depicted on the right) (Fig-
ure 3B, top-right panel). These analyses showed that the score
of enriched motifs for RUNX1 and C/EBP family members
increased in differential interactions upregulated after RUNX1-
ETO depletion, together with an increase in GFI1, MYB, and
MYC/MAX binding site occupancy. In contrast, and in concor-
dancewith our ChIP-seq data, AP-1motif enrichment decreased
in interactions that were lost after RUNX1-ETO depletion,
together with loss of activating TF (ATF) and nuclear factor kB
(NF-kB)motif occupancy.We also detected enrichment ofmotifs
in both gained and lost interactions. This was true for ETS-family
factors such as ERG and PU.1, but also for RUNX1, suggesting
that factors move to other sites as shown previously (Lichtinger
et al., 2012). To confirm this idea, we determined the distribution
of distance between RUNX1 binding and other TFs before and
after RUNX1-ETO depletion using the ChIP-seq data. This anal-
ysis showed a significant co-localization between AP-1 and
RUNX1 peaks before, but not after, RUNX1-ETO depletion. In
contrast, RUNX1 and C/EBPa show significant co-localization
after RUNX1-ETO depletion (Figure 3C). In spite of the appear-
ance of new RUNX1 binding sites after RUNX1-ETO depletion
(Ptasinska et al., 2012, 2014), no significant changes were
observed in the distribution of distance between RUNX1 and
LDB1 and LMO2 and PU.1 peaks (Figures S3F–S3H), indicating
no change in this type of factor collaboration. These analyses
suggest that RUNX1 cooperates with different factors regulating
different biological processes in control and RUNX1-ETO-
depleted cells. To examine TF cooperation after the onset of
monocytic differentiation, we performed a bootstrapping anal-
ysis (Figure 3D) in RUNX1-ETO-depleted and control cells that
identified occupied TF binding motifs co-localizing with high sig-
nificance within 50 base pairs (bp) as compared to the rest of the
active genome (highlighted in red). This analysis again confirmed
the strong co-association of occupied C/EBP and RUNX1motifs
in differentiated cells and AP-1, ETS, andRUNXmotifs co-occur-(C) Bar plots illustrating the distribution of distances between the binding sites o
distance between RUNX1 peaks in siMM and siRE cells and C/EBPa peaks in siM
peaks and JUND control peaks (bottom left) and JUND after R/E KD (bottom rig
(D) Bootstrapping analysis of the significance of co-localizing of footprinted mot
panel) after RUNX1-ETO depletion as compared to the rest of the genome. The he
to sampling by chance.
(E) Heatmap highlighting the percentage of day-4 Kasumi-1 DHSs with interaction
primary t(8;21) data. The t(8;21) and FLT3-ITD DHS/CHi-C patient data were dow
3028 Cell Reports 28, 3022–3031, September 17, 2019rences in control cells. Interestingly, the AP-1 or C/EBP motifs
were not preferentially footprinted in the DHSs shared between
control and knockout cells and did not co-localize with other mo-
tifs (Figure S3I), indicating that co-localizing (RUNX1-AP-1) sites
are part of the AML-specific cistrome. In summary, these ana-
lyses demonstrated that the establishment of specific RUNX1-
ETO-dependent cis-element interactions are mediated by the
cooperation of a limited set of constitutive and inducible TFs.
The depletion of RUNX1-ETO drives the loss and relocation of
TFs and thus the establishment of new interactions via new fac-
tor collaborations.
The Construction of Transcriptional Networks
Grounded in Multi-omics Data
The Kasumi-1 cell line is one of the best-studied human models
of t(8;21) AML with numerous multi-omics data available that
should be amenable to modeling approaches predicting tran-
scriptional network behavior in response to perturbation. So far
we have assigned factor binding site data only to their nearest
promoter. However, numerous studies have shown that such as-
signments were not accurate (Mifsud et al., 2015; Sanyal et al.,
2012). In our study, we found that only about 40% of all cis-reg-
ulatory elements in control cells interacted with their nearest pro-
moter. Our CHi-C data enabled us to assign DHSs containing
active cis-elements and footprinted regions to promoters (Data
S2). More than 70% of all DHSs assigned to their rightful pro-
moter in Kasumi-1 cells were also present in t(8;21) but not in
FLT3-ITD patients or normal CD34+ hematopoietic stem cell
(HPSCs; Figure 3E; Assi et al., 2019). To construct gene regula-
tory networks and to examine how these networks shift after
RUNX1-ETO depletion and differentiation, we used our footprint-
ing data (control and day-10 siRE) to assign occupied motifs to
specific TF families capable of binding to this motif (Table S1,
indicated as groups in Figure 4).We then plotted the connections
between factors and genes that were downregulated (Figure 4B,
blue ovals) or upregulated (Figure S4, red ovals) by at least 2-fold
following RUNX1-ETO depletion at day 10, with the former being
markers for the leukemic and the latter being markers for differ-
entiated states. We also highlighted which genes were RUNX1-
ETO targets (green boundary). This analysis shows a complex
web of interactions between effector genes (lined up at the
top) and TF encoding genes, many of which are known to
respond to RUNX1-ETO depletion, such as C/EBPA or IRF8.
The networks highlight the TFs involved in differentiation, again
showing that increased C/EBPa activity is the main driver of
the changes of the t(8;21) transcriptional network after RUNX1-
ETO depletion, with C/EBP family members binding to multiple
differentiation-specific cis-regulatory elements and driving the
upregulation of their respective genes (Loke et al., 2018;f the indicated TFs as determined by ChIP-seq. We measured the changing
M (top left) and siRE cells (top right), as well as the distance between RUNX1
ht).
ifs within day-10 DHSs for sites that are either lost (left panel) or gained (right
atmap shows the significance of motifs co-localizing within 50 bp as compared
s found in different patient groups indicating the similarity between cell-line and
nloaded from GEO: GSE108316 (Assi et al., 2019).
Figure 4. Differentially Expressed Genes af-
ter RUNX1-ETO Knockdown Are Regulated
by Different TF Networks
(A) Top panel: data analysis strategy. Transcrip-
tional network of downregulated (blue) non-TF
(effector) genes after RUNX1-ETO knockdown (top
rows) connected to genes encoding TF families
(bottom rows) as determined by digital footprinting
and CHi-C. Arrows going outward can come from
any TF family within a group; incoming arrows are
specific for each gene.
(B) Node and edge attributes.Ptasinska et al., 2014). An example of a downregulated gene
specific to the leukemic state includes UBASH3B, which has
previously been shown to regulate the proliferation of t(8;21) cells
(Goyama et al., 2016). Another such example is YES1, which,
together with another downregulated gene, MEIS2, is involved
inmaintaining leukemic growth (Vegi et al., 2016). AP-1members
are important for maintaining the leukemic growth phenotype, as
shown by expressing a dominant-negative FOS protein in t(8;21)
cells. Expression of this peptide downregulates the expression
of several cell cycle genes, including CCND2 (Martinez-Soria
et al., 2019), and blocks tumor growth in vivo (Assi et al., 2019).
Such examples of properly annotated RUNX1-ETO-responsive
genes with known function show the quality of our analysis
with respect to the prediction of important genes required for
AML maintenance. Last but not least, our studies serve as para-
digm for how high quality multi-omics data can be used to
generate in-depth information on the regulatory circuitries of a
specific type of AML.STAR+METHODS
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Antibodies
ETO Diagenode Cat# C15310197
RUNX1 (C-terminal epitope) Abcam Cat# 23980; RRID: AB_2184205
C/EBPa Abcam Cat# 40761; RRID: AB_726792
LDB1 Abcam Cat# 96799; RRID: AB_10679400
LMO2 R&D Cat# AF2726; RRID: AB_2249968
CTCF Abcam Cat# 70303; RRID: AB_1209546
JUND Santa Cruz Cat# sc74; RRID: AB_2130177
GAPDH Sigma Cat# F3165; RRID: AB_259529
Anti-Rabbit HRP Cell signalling Cat# 7074; RRID: AB_2099233
Anti-Mouse HRP Jackson Cat# 115-0350-62; RRID: AB_2338504
CD34 Monoclonal Antibody (4H11), PE eBioscience Cat# 12-0349-42; RRID: AB_1548680
c-Kit Monoclonal Antibody (104D2), FITC eBioscience Cat# 11-1178-42; RRID: AB_2572472
Oligonucleotides
Oligonucleotide sequences, see Table S2 This Paper NA
Chemicals, Peptides, and Recombinant Proteins
TruSeq Stranded mRNA with Ribo-Zero human assay Illumina Cat# 20020596
TruSeq RNA Sample Prep kit Illumina Cat#RS-122-2001
KAPA hyper Prep Kit Kapa Biosystems KK8500
KAPA Library Quantification kit Kapa Biosystems Cat#KK4824
MinElute Gel Extraction Kit QIAGEN Cat#28604
DNaseI Worthington, DPPF grade
AMPure XP beads Beckman Coulter Cat#A63882
NextSeq500 High output 150 cycles Illumina Cat#FC-404-2002
NextSeq500 High output 75 cycles Illumina Cat#FC-404-2005
Nucleospin RNA column Machery Nagel, 740955.50
OligoDT primer Promega C110A
Murine Moloney Virus reverse transcriptase Promega M170A
RNase Inhibitor Promega N261A
Sybr Green mix Applied Biosystems 4309155
Proteinase K Roche 03115801001
Di(N-succinimidyl) glutarate (DSG) Sigma-Aldrich 80424
MyOne Streptavidin C1 DynaBeads Invitrogen 65601
MyOne Streptavidin T1 DynaBeads Invitrogen 65001
Formaldehyde (Pierce, Thermos Scientific, USA 28906
(NEB)2 buffer NEB 37002
Critical Commercial Assays
Dead Cell Removal microbeads Miltenyi Biotec 130090101
Annexin V-APC/PI staining Ebiosciences 88-8007-74
High Sensitivity DNA Chips Agilent Technologies 5067-4626
RNA Pico Chips Agilent Technologies 5067-1513
High Pure PCR Product Purification Kit Roche 11732676001
SureSelect target enrichment Agilent Technologies 5190-4393
HindIII NEB R0104M
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
CHIP-seq data This study GSE121282
DNaseI-seq data This study GSE121282
RNA-seq data This study GSE121282
Capture HiC This study GSE117108
reprogramming ATAC-Seq Corces et al., 2016 GSE75384
Published ChIP-Seq Ptasinska et al., 2014 GSE60131
Experimental Models: Cell Lines
Kasumi-1 human cell line DSMZ ACC220
Software and Algorithms
Bowtie 2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
MACS2 Zhang et al., 2008 https://github.com/taoliu/MACS
Homer Heinz et al., 2010 http://homer.ucsd.edu/homer/motif/
Cufflinks v2.2.1 Trapnell et al., 2013 http://cole-trapnell-lab.github.io/cufflinks/
announcements/protocol-paper/
Bedtools Quinlan and Hall, 2010 https://bedtools.readthedocs.io/en/latest/
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
Wellington algorithm Piper et al., 2013 https://pythonhosted.org/pyDNase/
Illustrator Adobe System Software Ireland https://www.adobe.com/cn/products/cs6/
illustrator.html
ZEN Zeiss https://www.zeiss.com/microscopy/int/
microscope-cameras.html
GraphPad Prism 6.0 GraphPad Software https://www.graphpad.com/scientificsoftware/
prism/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Con-
stanze Bonifer (c.bonifer@bham.ac.uk).
This study did not generate new reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Line Culture
Cells were maintained in a humidified incubator at 37C with 5% CO2. t(8;21) Kasumi-1 cells were cultured in RPMI with 10% FCS
supplemented with 1% glutamine and 1% penicillin/streptomycin.
METHOD DETAILS
siRNA Mediated Depletion of RUNX1-ETO or LDB1
1x107 cells were electroporated using a EPI 3500 (Fischer, Germany) single 350 V pulse for 10ms. After electroporation, the cells re-
mained in their cuvettes for 10minutes before being directly added to RPMI-1640with 10%FCS, supplemented with penicillin/strep-
tomycin and glutamine at a concentration of 0.5 x106 cells per ml and returned to an incubator kept at 37C and 5% CO2. siRNA
sequences (SIGMA ALDRICH Germany) specific for the translocation breakpoint of RUNX1-ETO were 50 CCUCGAAAUCGUACU
GAGAAG 30 (sense) and 50- UCUCAGUACGAUUUCGAGGUU-30 (antisense). Control siRNA was 50-CCUCGAAUUCGUUCUGA
GAAG-30 (sense) with 50-UCUCAGAACGAAUUCGAGGUU-30 (antisense). siRNA sequences specific for LDB1 ON-TARGETplus
Human LDB1 siRNA SMARTpool (L-016010-00-0005, Dharmacon). siRNA was used at 200 nM.
RNA Extraction
RNA from Kasumi-1 cells was purified using a Nucleospin RNA column (Machery Nagel, France), according to manufacturer’s in-
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280 nMwavelengths. RNA has a greater absorbance in the 260 nMwavelength, Eukaryotic Total RNA PICOBioanalyser chip (Agilent
technologies, USA) allows visualization of the size of the RNA molecules and thus, demonstrates whether the sample is degraded
or not.
RNA Seq Libraries
RNA-seq libraries were prepared with a Total RNA Ribo-zero library preparation kit (with ribosomal RNA depletion) (Illumina, USA)
according to manufacturer’s instructions with the following alterations: 15 cycles of PCR was undertaken to amplify the library
and adaptors for multiplexing were used at a 1:4 dilution. Library quality was checked by running the samples on a Bioanalyser
and libraries were quantified using a Kapa library quantification kit (Kapa Biosystems, USA) and run in a pool of eight indexed libraries
in two lane of a HiSeq 2500 (Illumina, USA) using rapid run chemistry with 100bp paired end reads.
cDNA Synthesis
1 mg RNA was used to make cDNA with 0.5 mg OligoDT primer, Murine Moloney Virus reverse transcriptase and RNase Inhibitor
(Promega, USA) according to the manufacturer’s protocol.
Real-Time Polymerase Chain Reaction
RT-PCR was performed using Sybr Green mix (Applied Biosystems, UK), at 2x dilution. Primers were used at 100 nM final concen-
tration. cDNA was diluted 1:50 depending on expression levels of targets. A 7900HT system (Applied Biosystems, UK) was used to
perform qPCR. Primers used in this project are listed in Table S2.
Dead Cell Removal and Annexin V/PI Staining for Flow Cytometry
Dead cell removal was performed using negative selection on aMS column following incubation with Dead Cell Removal microbeads
(Mitenyi Biotech, USA) as permanufacturer’s instructions. Dead cell removal was performed on all samples prior to RNA extraction or
DHSs mapping. Annexin V-APC/PI staining (Ebiosciences, USA) or was performed according to manufacturer’s instructions.
DNaseI Hypersensitivity Site Mapping
Prior to DNaseI digestion, apoptotic cells were removed using the DeadCell Removal Kit (Miltenyl Biotech, UK) as permanufacturer’s
instructions. 3x 107 Kasumi-1 cells were suspended in 1 mL DNase I buffer (0.3M sucrose, 60 mM KCl, 15 mM NaCl, 5 mM MgCl2,
10mMTris pH7.4). Digestion on 4.5x106 cells was performed with DNase I (Worthington, DPPF grade) at 80 units/ml in DNase I buffer
with 0.4%NP-40 and 2mMCaCl2 at 22C for 3minutes. The reactionwas stoppedwith cell lysis buffer (0.3MNaAcetate, 10mMEDTA
pH7.4, 1%SDS) with 1mg/ml Proteinase K and incubated at 45Covernight. The digestedDNase Imaterial was treatedwith RNase A
(Sigma Aldrich, Germany) at a final concentration of 100 mg/ml at 37C for 1 hr. Genomic DNAwas extracted using phenol/chloroform
method: an equal volume of phenol was added to the reaction and placed on a rotator wheel for 45 minutes. This was centrifuged for
5 minutes at 16000 x g at room temperature. The top layer was transferred to a new tube and the process was repeated sequentially
with phenol/chloroform and chloroform. After purification by chloroform extraction, genomic DNAwas precipitated with ethanol. This
was pelleted by centrifugation for 5minutes, at 16000 x g at 4C. The pellet was resuspendedwith 70%ethanol and centrifugation for
5 minutes, at 16000 x g at 4C. The pellet was air-dried and dissolved by Tris-EDTA (40 mM Tris Acetate 1 mM EDTA). Digestion was
checked visually by running the samples on a 0.7% agarose gel and by RT-PCR evaluating the ratio of open (TBP promoter) to closed
regions ofDNA (chromosome18) and active gene body (beta-actin) to prevent selection of over digested samples. Primers used in this
project are listed in Table S2. Subsequently, between 2 to 10 mg of DNase I-digested DNA (depending onmaterial available) were run
on a 1.5%agarose gel for selection of shorter fragments to increase the fraction of fragments captured fromDHSs. Prior to loading on
gel, the purified DNA was treated again with RNase A (Sigma Aldrich, USA) at a final concentration of 100 mg/ml at 37C for 1 hr.
50-300 bp fragments were isolated and purified from the gel using aMinElute gel extraction kit (QIAGEN, USA) as per manufacturer’s
instructions and validated by qPCR. Following this, the size selected sample was validated again by RT-PCR, this time using shorter
amplicons to enable detection of the shorter fragments enriched by the size selection process.
Library Production of DNase I Material for High Throughput Sequencing
After size selection, a library was prepared using KAPA Hyper Prep Kit sample preparation kit (Kapa Biosystems, USA) as per man-
ufacturer’s protocol. After PCR a final size selection step was performed by running the library on 2% TAE gel, followed by excision of
190-250 bp sized gel fragment. The library was purified from the gel using a MinElute gel extraction kit (QIAGEN, USA). The quality of
the libraries was assessed on an Agilent 2100 Bioanalyser. Libraries were subsequently run on two lanes of an Illumina HiSeq 2500
flow-cell for transcription factor footprinting, or as part of 12 indexed libraries in one lane of a NextSeq500 (Illumina, USA) for DHS
mapping alone.
ChIP-qPCR and ChIP-Seq Library Preparation
Double Cross-Linking
A double cross-linking technique was used to optimize the efficiency of transcription factor chromatin immunoprecipitation (ChIP).
2x107 cells were washed thrice in PBS. Di(N-succinimidyl) glutarate (DSG) (Sigma-Aldrich, Germany) at 850 mg/ml was added toe3 Cell Reports 28, 3022–3031.e1–e7, September 17, 2019
2x107 cells per ml and were incubated for forty-five minutes. Cells were washed four times and fixed with 1% formaldehyde
(Pierce, Thermos Scientific, USA) for tenminutes. Glycine to produce a final concentration of 100mMwas added to stop the reaction.
The pellet was washed again with PBS. Buffer A (HEPES pH 7.9 10 mM, EDTA 10 mM, EGTA 0.5 mM, Triton x100 0.25%, complete
mini protease inhibitor cocktail (PIC) 1x (Sigma-Aldrich, Germany) was added for 10 mins at 4C and removed by centrifugation at
500 g for 5 minutes. This was repeated with buffer B (HEPES pH 7.9 10 mM, EDTA 1 mM, EGTA 0.5 mM, Triton x100 0.01%, PIC 1x).
The residual nuclei were then spun down at 16000 x g at 4C for 5 minutes and aliquoted at 2x107 cells for 4 immunoprecipitations.
Chromatin Immunoprecipitation (ChIP)
Each aliquot of 2x107 cells was re-suspended in 600 mL of sonication buffer (Tris-HCL pH 8 25mM,NaCL 150mM, EDTA 2mM, Triton
100x 1%, SDS 0.25%, Protease inhibitor cocktail (PIC) 1x). 300 mL of nuclei in sonication buffer was placed in each polystyrene tube
and sonicated at 75% amplitude, 26 cycles: 30 s on and 30 s off per cycle (Q800, Active Motif, USA). Subsequently, 1.2ml of dilution
buffer (Tris-HCL pH8 25 mM, NaCL 150 mM, EDTA 2 mM, Triton 100x 1%, glycerol 7.5%, PIC 1x) was added to the pooled post
sonicationmaterial. This was divided equally between four immunoprecipitations (with 5%of input taken for validation). 20 mL protein
G beads (Diagenode, Belgium) were washed twice with 500 mL of 50 mM citrate phosphate buffer and once with 100 mM sodium
phosphate. 4 mg antibody ETO (Santa Cruz) or 4 mg antibody AML1-ETO (15310197, Diagenode), or RUNX1 (Ab23980, Abcam) or
4mg antibody C/EBPa (A2814, Santa Cruz) or 2mg antibody LBD1 (96799, Abcam) or 2mg antibody LMO2 (AF2726, R&D) or 2mg anti-
body CTCF (70303, Abcam) or 2mg JUND (sc74, Santa Cruz) was added to 10 mL 100 mM sodium phosphate, 0.5% BSA and incu-
bated with protein G beads at 4C for 1 hour. Chromatin was then added to the protein G beads with antibody and returned to 4C for
4 hours. Unbound chromatin was separated from the beads by magnet and the attached beads were washed by buffer 1 (Tris HCL
20 mM, NaCl 150 mM, EDTA 2 mM, Triton x100 1%, SDS 0.1%), twice with buffer 2 (Tris HCL 20 mM, NaCl 500 mM, EDTA 2 mM,
Triton x100 1%, SDS 0.1%), LiCL buffer (Tris HCL 10 mM, LiCl 250 mM, EDTA 1 mM, NP40 0.5%, sodium deoxycholate 0.5%) and
finally twice with wash buffer 4 (Tris HCL pH8, 10 mM, NaCl 50 mM, EDTA 1mM). The column was eluted twice with 50 mL buffer
(NaHCO3 100 mM and SDS 1%) and the eluant containing the chromatin was pooled. Crosslinks were reversed by incubating the
samples at 65C overnight in 500 mM NaCl, 500 mg/ml proteinase K. DNA was purified by Ampure beads (Beckman Coulter,
USA), as above, with the DNA eluted with 50 mL water. Validation of the ChIP was performed by qPCR using a standard curve of
genomic DNA from untreated Kasumi-1 cells (10ng/ ml followed by serial 1:5 dilutions). The input material was diluted 1:5 with water.
Primers used in this project are listed in Table S2. Validation was analyzed as a ratio of the qPCR signal from the ChIP material over
the input.
Library Production of ChIP Material for High Throughput Sequencing
Libraries for high throughput sequencing were prepared using the Tru-seq DNA sample preparation kit (Illumina, USA) or Kapa
HyperPrep kit (Kapa Biosystems, USA), as per manufacturer’s protocol. 18 cycles of PCR was performed and 200-350bp fragments
were size selected by running the samples in an agarose gel. Libraries were purified from the gel using a MinElute Gel extraction kit
(QIAGEN, USA). Libraries were validated by qPCR, with an analysis of the ChIP signal of a positive control region (e.g., PU.1 3H
enhancer) over a negative control region (e.g., IVL). Finally, libraries were quantified by Kapa library quantification kit (Kapa Bio-
systems, USA) and run in a pool of four indexed libraries in one lane of a HiSeq 2500 (Illumina, USA) or 12 indexed libraries in one
lane of a NextSeq 500 (Illumina, USA) using 50 cycle single-end reads.
Circularized Chromosome Conformation Capture (4C-seq)
4C analysis was performed exactly as described in Gro¨schel et al. (2014). 1x107 Kasumi-1 cells, transfected with mismatch siRNA
(siMM) or siRNA specific to siRUNX1-ETO (siRNA), were fixed with 2% formaldehyde and incubated for 10 minutes at room temper-
ature. 1.425mL of 1Mglycine was added to quench the cross-linking reaction. Fixed cells were immediately centrifuged for 8minutes
at 4C, 500 xg. Supernatant was removed and the pellet resuspended in 1ml lysis buffer (500ml 1M TRIS pH 7.5, 300ml 5MNaCl, 100ml
0.5M EDTA, 250ml 20% NP-40 and 100ml Triton X-100 made up to 10ml with H2O) and incubated at room temperature for 5 minutes,
followed by 5minutes at 65C. Cells were then kept on ice while complete cell lysis was determined via Trypan blue (GIBCO) staining.
Cells were centrifuged at 800 xg for 5 minutes and the pellet was taken up in 440 ml H20 and 60 ml 10X RE buffer 2 (NEB). 15 ml of SDS
was added and the tube placed at 37C for 1 hour. 75 ml of 20% Triton X-100 was added and the tube incubated at 37C for 1 hour. A
5 ml aliquot was removed as an ‘undigested control’ sample before 200 units of the restriction enzymeDpnII was added. The tubewas
incubated for 4 hours at 37C, and then another 200 units of DpnII was added, followed by an overnight 37C incubation. The
following day 200 units of DpnII was added for 4 hr at 37C. A 5 ml aliquot was removed as a ‘digested control’ sample. To this, along
with the ‘undigested’ sample, 90 ml of 10mM Tris pH 7.5 and 5ml Proteinase K (10 mg/ml) was added to reverse the cross links. These
control samples were run on a 0.6% agarose gel to assess the digestion efficiency. All 37C incubations were conducted in a heated
block, shaking at 900 RPM. DpnII was selected as the restriction enzyme as it functions in SDS, and combined with the second re-
striction enzyme (Csp6I) it generates restriction fragments near the target loci, with a suitable size for efficient ligation and PCR ampli-
fication. Both of these enzymes are 4bp cutters, so will cut the genome into 256 bp fragments, on average. This allows for a high
resolution assay. The DpnII was inactivated by incubation at 65C for 20 minutes. On ice, 700 ml of 10X ligation buffer, 7 mL of
milli-Q H20 and 10 ml T4 Ligase (Roche 5U/ml) were added then samples were incubated overnight at 16C. The following day, to
assess ligation efficiency, a 100 ml aliquot of the sample was taken as the ‘ligated control’. The crosslinks were reversed as above
and the sample run on a 0.6% agarose gel. To reverse the crosslinks, 30 ml Prot K (10mg/ml) was added and samples were left over-
night at 65C. The next day, 30 ml RNase A (10mg/ml) was added and samples were incubated for 45 minutes at 37C. DNA was
extracted by adding 7 mL phenol-chloroform. Samples were mixed thoroughly then centrifuged at 3000 xg at room temperature.Cell Reports 28, 3022–3031.e1–e7, September 17, 2019 e4
The water phase was transferred to a new 50 mL tube to which 7 mL of milli-Q H20, 7 ml of glycogen, 1.5 mL 2M NaAC pH 5.7 and
35 mL ethanol was added. Samples were placed at –80C overnight. The next day samples were centrifuged at 4C for 30 min,
3000 xg. The supernatant was removed and 10 mL of cold 70% ethanol was added. Samples were centrifuged again for 15 min,
3000 xg at 4C. The supernatant was removed and the pellet left to dry at room temperature. The pellet was dissolved in 150ml
10mM Tris pH 7.5. Each sample was transferred to a 1.7 mL tube, 50 ml 10X restriction buffer and 50 units of the restriction enzyme
Csp6I (Fermentas # ER0211) was added and the volume made up to 500 ml with milli-Q H20. After an overnight incubation, 500 RPM
shaking, at 37C, a 5 ml aliquot of the sample was taken. This ‘digestion control’ was run on a 0.6% agarose gel. The enzyme was
inactivated as previously describe and the samples transferred to a 50 mL tube. 1.4 mL of 10X ligation buffer and 20 ml of ligase
(100 U) (Roche Catalog # 10799009001) was added, then the reaction made up to 14ml with milli-Q H2O. After an overnight ligation
at 16C, 1.4ml 2MNaAC pH 5.6, 14ml glycogen and 35ml of 100% ethanol were added. Samples were stored at –80C overnight. The
next day samples were centrifuged at 4C for 45 minutes, at 3750 RPM. The supernatant was removed and 15 mL of cold 70%
ethanol was added. The samples were then centrifuged again for 15 minutes, at 20C and 3750 RPM. Again, the supernatant was
removed and the pellet then left to dry at room temperature. Once dry the pellet was dissolved in 150 ml 10mM Tris pH 7.5 at
37C. Samples were then purified using a QIAquick PCR purification kit, according to the manufacturer’s protocol. Samples were
eluted in 50 ml 10mM Tris pH 7.5 and pool samples. DNA concentration of each 4C template was determined via analysis with a
NanoDrop 2000 (Thermo Scientific). Restriction fragments greater than 350 bp and within 2kb of the target genomic region were
selected as viewpoint fragments, dependent on the ability to design specific primers. A 50 Illumina adaptor sequence was added
so the inverse-PCR products did not need further processing prior to sequencing. Reading primers were designed as close to the
primary restriction site as possible, to reduce reads from the known viewpoint sequence. Non-reading primers were designed to re-
gions less than 120kb from the secondary restriction site. 200 ng of 4C template was used per PCR reaction. For each viewpoint and
template, 16 PCR reactions were conducted using an Expand Long Template system (ROCHE # 11681834001) (see Table S2 for
primer sequences). The pooled PCR products (total volume 800 ml) were then purified using the High Pure PCR Product Purification
Kit (Roche cat. no. 11732676001), to remove any adaptor containing primers (< 120 bp). Samples were centrifuged to pellet any
beads that escaped the column. The supernatant was taken, then the concentration and purity of this 4C template was assessed
by a NanoDrop 2000 (Thermo Scientific) (260/280 ratio >2 and 260/230 ratio >1.8 was required). The libraries were then visualized
on a 1.5% agarose gel. All 4 of the 4C libraries were pooled, and then multiplexed sequencing was performed on the HiSeq 2500
platform. Individual fragment counts were calculated for every 1kb bin. A median was calculated, with a 3kb sliding window, and
data from both biological replicates was merged. The R package DESeq2 was used to calculate the log2 fold change (RUNX1/
ETO knockdown versus control) at the local genomic coordinates. Viewpoint specific 4C-seq PCR primers used in this project are
listed in Table S2.
Hi-C Library Generation
Hi-C library generation was carried out as described previously (Mifsud et al., 2015; Lieberman-Aiden et al., 2009), with the following
modifications which were detailed with the following modifications. After fixation in 2% formaldehyde for 5 min, 50 million Kasumi-1
cells were homogenized in 10 mL of ice-cold lysis buffer ten times on ice with a tight pestle, incubated on ice for 15 min and then
homogenized a further ten times. After overnight digestion with HindIII at 37C, DNA ends were labeled with biotin-14–dATP (Life
Technologies) in a Klenow end-filling reaction. After phenol-chloroform purification, the DNA concentration was measured using
Quant-iT PicoGreen (Life Technologies), and 40 mg of DNA was sheared to an average size of 400 bp, using the manufacturer’s in-
structions (Covaris). The sheared DNA was end repaired, adenine tailed, and double size selected using AMPure XP beads to isolate
DNA ranging from 250 to 550 bp in size. Ligation fragments marked by biotin were immobilized using MyOne Streptavidin C1
DynaBeads (Invitrogen) and ligated to paired-end adaptors (Illumina). The immobilized Hi-C libraries were amplified using PE PCR
1.0 and PE PCR 2.0 primers (Illumina) with 8 PCR amplification cycles.
Biotinylated RNA Bait Library Design
Biotinylated 120-mer RNA baits were designed to target both ends of HindIII restriction fragments that overlap Ensembl promoters of
protein-coding, noncoding, antisense, snRNA, miRNA and snoRNA transcripts. A target sequence was valid if its GC content ranged
between 25 and 65% and the sequence contained no more than two consecutive Ns and was within 330 bp of the HindIII restriction
fragment terminus.
Promoter Capture Hi-C
Capture HiC of promoters was carried out with SureSelect target enrichment, using the custom-designed biotinylated RNA bait li-
brary and custom paired-end blockers according to the manufacturer’s instructions (Agilent Technologies). After library enrichment,
a post-capture PCR amplification step was carried out using PE PCR 1.0 and PE PCR 2.0 primers with 4 PCR amplification cycles.
CHi-C libraries were sequenced on the Illumina HiSeq 1000 platform.
Western Blotting
Protein extracts were prepared using a co-immunoprecipitation kit (Active Motif, USA). Protein extracts were quantified using Brad-
ford protein reagent (Bio-Rad, USA) and 595nM absorbance quantified by spectrophotometry. Absolute concentrations were deter-
mined using a standard curve from a known concentration of BSA (Pierce, USA). Protein extracts was run on an acrylamide gel and
transferred to nitrocellulose membrane. The antibodies used in this project are listed in Table S2. Enhanced chemiluminescence by
SuperSignal PICO (Thermos Scientific, USA) was used to develop the membrane. Chemiluminescence was detected using either
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Antibody Staining for Flow Cytometry
15x104 were centrifuged at 300xg and washed with MACS buffer. The cell pellet was re-suspended in 50 ml MACS buffer and 2 ml of
antibody was added and incubated for 15 minutes at 4C in the dark. After incubation, the cells was washed once with MACS buffer
before resuspension in 300 ml MACS buffer and analyzed on Cyan ADP (Beckman Coulter, USA). Data were analyzed on Summit 4.3
(Beckman Coulter, USA). Antibodies used in this project are listed below. CD34 Monoclonal Antibody (4H11), PE, eBioscience
Cat #12-0349-42; CD117 (c-Kit) Monoclonal Antibody (104D2), FITC, eBioscience Cat #11-1178-42
QUANTIFICATION AND STATISTICAL ANALYSIS
DNaseI Sequencing Data Analysis
DNaseI sequences from all experiments were mapped onto the reference human genome (hg38), with Bowtie version 2.3.1 (Lang-
mead and Salzberg, 2012) using default parameters. Low quality reads were trimmed using Trimmomatic-0.36 (Bolger et al., 2014)
and quality control (QC) statistics were obtained using FastQC tools. Unique aligned reads were used for downstream analysis.
DNaseI Hypersensitive Sites (DHSs) were called with MACS2 using callpeak function (nomodel, call-summits and q = 0.005 param-
eters) (Zhang et al., 2008). Clustering of DNaseI-seq samples was carried out using themergedDHSs. The number of reads that map-
ped to these DHSs was counted in a 400bp window centered on the DHS summit, and subsequently normalized to total sample size
using DEseq2 (Love et al., 2014). Pearson correlation coefficients were then calculated for each pair of samples using the log2 of the
normalized read counts, and then hierarchically clustered using Euclidean distance and complete linkage clustering of the correlation
matrix in R.
ChIP Sequencing Data Analysis
ChIP sequencing reads were aligned to the human genome version hg38 with Bowtie version 2.3.1 (Langmead and Salzberg, 2012).
Reads that mapped uniquely to the genome were retained and duplicated reads were removed using the MarkDuplicates function in
Picard tools (http://broadinstitute.github.io/picard/). Peaks were identified with MACS version 1.4.2 (Zhang et al., 2008) and DFilter
software (Kumar et al., 2013) with recommended parameters (-bs = 100 -ks = 50 –refine). Peaks common to both peak calling
methods were considered for further analysis.
Average Tag Density Profile and Heatmap
The tag density and average profiles for Figures S1D and S2E were generated by calculating the tag density normalized as coverage
per million within 400bp windows of the DNaseI peak summit. The read counts for all union peaks were computed. Coverages were
calculated for all union peaks and ranked by log2 fold change. Heatmap images were generated via Java TreeView (http://jtreeview.
sourceforge.net/) and average profiles were plotted using R.
RNA-Seq Data Analysis
RNA-seq reads downloaded from GSE54478 were aligned to the human genome hg38 build with STAR (Dobin et al., 2013) using
ENCODE recommend parameters. Separate density profiles for the positive and negative strand were generated using bedtools.
Cufflinks (Trapnell et al., 2013) was used to calculate the expression values as Fragments Per Kilobase per Million aligned reads
(FPKM) from the aligned RNA-seq data and differentially expressed genes were extracted using the limma R package (Ritchie
et al., 2015). All genes with p value% 0.01 were considered with at least 2-fold changes between before and after RUNX1-ETO knock
down.
Promoter Capture HiC Data Analysis
The CHi-C paired-end sequencing reads were aligned to the human genome hg38 build using HiCUP pipeline (Wingett et al., 2015).
The raw sequencing readswere initially separated andmapped against the reference genome. The readswere then filtered for exper-
imental artifacts and duplicate reads, and then re-paired. Statistically significant interactions were called using GOTHiC package
(Mifsud et al., 2017) and HOMER software (Heinz et al., 2010). This uses a cumulative binomial test to detect interactions between
distal genomic loci that have significantly more reads than expected by chance, by using a background model of random interac-
tions. This analysis assigns each interaction with a p value, which represents its significance. Differential interactions between control
and after RUNX1-ETO knock-down were determined with HOMER (Heinz et al., 2010), p value cutoff with at least 0.01 was
considered.
4C-Seq Data Analysis
4C-seq data analysis was performed using 4Cseqpipe, as described in van de Werken et al. (2012). Sequence extraction, mapping,
normalization, and plotting of cis-contact profiles around PU.1 promoter and enhancer viewpoints were done using packages called
by 4Cseqpipe tools. Custom restriction site tracks were built using the -build_re_db option of 4Cseqpipe for the hg19 human
genomic version with HindIII as first and second restriction cutters. 4C reads were mapped to the custom hg19 tracks with the in-
built 4Cseqpipe mapper. Near-cis domainograms were generated for PU.1 viewpoints using the median stat type and plotting the
20th and 80th quantile of the distribution of normalized contact intensities for 5kb sliding windows.Cell Reports 28, 3022–3031.e1–e7, September 17, 2019 e6
Motif Identification and Clustering
De novomotif analysis was performed on peaks using HOMER (Heinz et al., 2010). The annotatePeaks function in HOMERwas used
to find occurrences of motifs in peaks. In this case we used known motif position weight matrices (PWM) from HOMER database.
Motif clustering: Digital footprinting of DNaseI high-depth sequencing data was performed using the Wellington algorithm (Piper
et al., 2013) with FDR = 0.01. For the heatmap that shows hierarchical clustering of motif occurrences within specific and common
footprints (Figure 3D). The distance between the centers of each motif pairs was calculated and the motif frequency was counted if
the first motif was within 50bps distance from the second motif. Z-scores were calculated from the mean and standard deviation of
motif frequencies observed in random sets using bootstrapping analysis. For bootstrapping, peak sets with a population equal to that
of the footprinted peaks were randomly obtained from the union of DNase-Seq footprints.
DATA AND CODE AVAILABILITY
TheCHIP-seq data, DNaseI-seq data, and RNA-seq data generated during this study are available at GEO: GSE121282. The Capture
HiC data generated during this study are available at GEO: GSE117108. The published article includes reprogramming ATAC-Seq
(Corces et al., 2016) GEO: GSE75384 analyzed during this study. The published article includes Published ChIP-Seq (Ptasinska
et al., 2014) GEO: GSE60131 analyzed during this study.e7 Cell Reports 28, 3022–3031.e1–e7, September 17, 2019
